Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lowered its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 34.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 314,939 shares of the company's stock after selling 163,501 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.46% of Amylyx Pharmaceuticals worth $1,190,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMLX. Blue Trust Inc. grew its holdings in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after acquiring an additional 4,883 shares during the period. XTX Topco Ltd increased its position in shares of Amylyx Pharmaceuticals by 12.0% in the fourth quarter. XTX Topco Ltd now owns 53,376 shares of the company's stock valued at $202,000 after buying an additional 5,704 shares in the last quarter. Northern Trust Corp raised its stake in shares of Amylyx Pharmaceuticals by 11.8% during the 4th quarter. Northern Trust Corp now owns 106,564 shares of the company's stock worth $403,000 after buying an additional 11,214 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $45,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $45,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Stock Up 3.0%

Shares of AMLX stock traded up $0.16 on Tuesday, reaching $5.52. 1,582,420 shares of the stock were exchanged, compared to its average volume of 1,221,679. The firm has a 50 day moving average of $4.17 and a two-hundred day moving average of $4.19. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27. The stock has a market cap of $492.06 million, a P/E ratio of -1.45 and a beta of -0.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. On average, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Bernhardt G. Zeiher acquired 10,000 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were bought at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $37,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Camille L. Bedrosian sold 12,425 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $43,114.75. Following the sale, the insider now owns 194,375 shares of the company's stock, valued at $674,481.25. This represents a 6.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 48,980 shares of company stock valued at $168,627. Company insiders own 11.70% of the company's stock.

Analysts Set New Price Targets

AMLX has been the subject of a number of recent research reports. Mizuho raised their price objective on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 14th. Leerink Partnrs upgraded Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the company from $4.00 to $10.00 in a report on Wednesday, May 7th. Finally, HC Wainwright boosted their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $9.83.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.